Wegovy Injections: How They Work, Suitability & What a Pharmacy Consultation Involves
Wegovy is a prescription medicine containing semaglutide. The injectable form is used once a week for weight management in people who meet defined clinical criteria, alongside a reduced-calorie diet and increased physical activity. It works mainly by acting on GLP-1 receptors involved in appetite and food intake, which can help people feel fuller and reduce hunger.
Wegovy is not suitable for everyone, and meeting a BMI threshold does not automatically mean it should be prescribed. A clinical assessment needs to consider your health, other medicines, pregnancy or pregnancy plans, previous problems such as pancreatitis, significant digestive symptoms, diabetes treatment and the risks and benefits for you personally. This guide explains the injectable form of Wegovy and the kinds of checks that may form part of a pharmacy or prescribing consultation. It does not replace an individual assessment.
What is a Wegovy injection?
Wegovy is a brand of semaglutide used for weight management. Semaglutide is a GLP-1 receptor agonist, which means it acts in a similar way to the naturally occurring GLP-1 hormone. Current UK product information describes injectable Wegovy as a subcutaneous injection, meaning it is injected under the skin. This article focuses on the injectable form; Wegovy is also available in other formulations, so the exact product and instructions on your prescription and patient leaflet matter.
For adults, the licensed weight-management indication includes people with obesity, defined in the product information as a BMI of 30 kg/m² or above, and people with a BMI from 27 kg/m² to below 30 kg/m² who also have at least one weight-related health condition. The medicine is licensed as an addition to a reduced-calorie diet and increased physical activity, not as a replacement for those measures.
The product information also includes an indication for some adolescents aged 12 years and over who have obesity and a body weight above 60 kg. That does not mean every private or pharmacy service treats people under 18. Individual services can have narrower age and eligibility rules, and a prescriber must decide whether treatment is appropriate.
How do Wegovy injections work?
Semaglutide activates GLP-1 receptors. GLP-1 is involved in the regulation of appetite and calorie intake, and semaglutide acts on areas of the brain associated with hunger, fullness and food intake. In practical terms, some people find that they feel less hungry, become satisfied with smaller amounts of food or experience fewer food cravings while taking treatment.
Semaglutide also has effects on blood glucose. It can stimulate insulin release and reduce glucagon when blood glucose is high, and it can delay gastric emptying to some extent. These effects are relevant when a person has diabetes or takes medicines that can lower blood glucose, because the prescriber may need to consider the risk of hypoglycaemia and whether other treatment needs adjustment.
The injection is taken weekly, but the dose is not something to choose independently. Wegovy is introduced and adjusted in stages to improve tolerability, particularly because gastrointestinal side effects are more common while the dose is being increased. Exact dosing belongs in your current prescription, the latest patient information leaflet and prescriber advice. Do not copy a dose schedule from an old article or another person’s treatment plan.

Who may be assessed for Wegovy?
A Wegovy assessment is not simply a yes-or-no BMI check. The prescriber needs enough information to decide whether the medicine is licensed and clinically appropriate, whether another approach may be safer, and what monitoring is needed.
For an adult, the starting point is usually whether the licensed BMI and weight-related health criteria are met. The assessment may also consider previous weight-management efforts, current health conditions, medicines, treatment goals and whether the person can use the medicine safely alongside dietary and physical-activity changes.
NHS eligibility is more restrictive than the full marketing authorisation. NICE recommends semaglutide for specific adults within specialist weight-management services and with defined BMI and comorbidity criteria. Private prescribing is different from NHS access, but it still requires a valid prescription and an appropriate clinical assessment. A private consultation should not be presented as a guarantee that Wegovy will be prescribed or supplied.
When might Wegovy be unsuitable or need extra caution?
The formal contraindication in the current injectable Wegovy product information is hypersensitivity to semaglutide or the listed ingredients. A safe assessment also needs to identify circumstances where treatment should not be used or where extra caution, monitoring or specialist input may be required.
Semaglutide should not be used during pregnancy. If pregnancy occurs, the medicine should be stopped and medical advice sought. Current product information advises stopping semaglutide at least two months before a planned pregnancy because it remains in the body for a prolonged period. It should also not be used while breastfeeding.
A previous history of pancreatitis does not appear as the formal contraindication in the current SmPC, but the medicine has not been studied in that group and should be used with caution. Severe gastroparesis is another important consideration: semaglutide can cause gastrointestinal effects and is not recommended in severe gastroparesis. People with diabetes may need additional review, particularly if they use insulin or a sulfonylurea, or if they have diabetic retinopathy.
You should also tell the clinician if you are due to have an operation or procedure under general anaesthesia or deep sedation. GLP-1 medicines can delay stomach emptying, and this may be relevant to aspiration risk around anaesthesia. The surgical or anaesthetic team should know that you use semaglutide.
These examples are not a complete suitability checklist. Your prescriber needs your full medical history and an accurate list of prescription medicines, over-the-counter medicines and relevant supplements.
What happens in a pharmacy or prescribing consultation?
The exact process varies by provider, but a responsible consultation should collect enough information for a prescriber to make a safe, individual decision. Depending on the service, this may include:
- confirming your identity, age, height, weight and BMI;
- discussing weight-related health conditions and relevant medical history;
- reviewing prescription medicines and other treatments you use;
- asking about diabetes and medicines that may cause low blood glucose;
- checking pregnancy, breastfeeding and pregnancy plans where relevant;
- discussing previous pancreatitis, significant gastrointestinal symptoms, gastroparesis, gallbladder problems or other relevant history;
- asking about eye disease or sudden visual symptoms, particularly where diabetes is present;
- considering upcoming surgery, anaesthesia or sedation;
- reviewing previous weight-management treatment, eating patterns, physical activity and realistic goals; and
- explaining expected benefits, common side effects, important warning symptoms, how follow-up works and what to do if problems develop.
Some services may request photographs, measurements, blood tests, blood pressure readings or information from your GP record when clinically necessary. Others may arrange an in-person or remote consultation. The important point is that the information must be sufficient for safe prescribing; a quick checkout process should never replace clinical assessment.
Before starting, know which questions need a clear answer
Before you commit to treatment, make sure you understand who is prescribing, how the medicine will be supplied, what follow-up is included and how to get help if you develop side effects. You should know which product and formulation you have been prescribed, how to store and use it, what to do if you miss a dose and when the service expects you to check in again.
If you are using a private route, use a regulated pharmacy or service and be cautious of sellers that offer semaglutide without a proper prescription or assessment. The NHS also advises people seeking private semaglutide to obtain it from a registered pharmacy because falsified weight-loss medicines are a recognised risk. Never share injection pens or use medicine supplied for somebody else.
What monitoring may be needed after treatment starts?
Monitoring is not only about the number on the scales. Follow-up should consider whether the medicine is tolerated, whether it is providing meaningful benefit, whether side effects are manageable and whether any new health issues or medicines change the risk-benefit balance.
Early follow-up often pays particular attention to nausea, vomiting, diarrhoea, constipation and abdominal symptoms, because gastrointestinal effects are among the most frequently reported adverse reactions with semaglutide. Persistent vomiting or diarrhoea can lead to dehydration. This matters especially for people with kidney problems, so maintaining fluid intake and seeking advice when symptoms are significant is important.
The prescriber may also review weight change, nutrition, physical activity, treatment adherence and whether continuation remains appropriate. Current injectable product information says that if an adult has not lost at least 5% of their initial body weight after six months of treatment, a decision is needed about whether treatment should continue, taking the individual benefit-risk profile into account.
If you have diabetes, monitoring may need to include blood-glucose control and the effect of other diabetes medicines. Do not reduce insulin, sulfonylureas or other prescribed treatment yourself unless the clinician responsible for your care advises you to do so.
What side effects can Wegovy injections cause?
The most frequently reported side effects with semaglutide are gastrointestinal. These include nausea, diarrhoea, vomiting and constipation. Abdominal discomfort, indigestion and other digestive symptoms can also occur. Side effects are often more noticeable while the dose is being increased, although experiences vary and symptoms should not simply be ignored if they are severe or persistent.
There are also less common but important risks. Acute pancreatitis has been reported with GLP-1 receptor agonists, including semaglutide. Gallstones and gallbladder inflammation can occur. Severe allergic reactions are rare but require urgent treatment. Current UK safety information also highlights a very rare eye condition called non-arteritic anterior ischaemic optic neuropathy, or NAION, which can cause sudden or worsening loss of vision.
The patient information leaflet supplied with your medicine gives the full current side-effect list. Read it and keep it available while you are using treatment.

Which symptoms need urgent medical attention?
Seek urgent medical help if you develop severe, persistent abdominal pain, particularly if it spreads to the back or occurs with nausea or vomiting, because this can be a sign of acute pancreatitis.
Urgent assessment is also needed for a sudden loss of vision or rapidly worsening eyesight. Severe allergic-reaction symptoms such as swelling of the face, lips, tongue or throat, breathing difficulty, wheezing, severe dizziness or collapse need immediate medical attention.
If vomiting or diarrhoea is persistent and you are struggling to keep fluids down, seek clinical advice because dehydration can become significant. If you are unsure whether a symptom is urgent, use NHS 111 for advice, or 999/A&E for a medical emergency.
Wegovy is part of a wider weight-management plan
Wegovy is licensed to be used alongside a reduced-calorie diet and increased physical activity. Medication can change appetite, but it does not remove the need to think about nutrition, activity, sleep, alcohol, smoking, mental wellbeing and the practical habits that support long-term health.
A good plan should also avoid unrealistic promises. Weight loss varies between individuals, and there is no guaranteed amount or speed of weight loss. The aim of monitoring is to judge whether the treatment is helping enough to justify continuing and whether it remains safe.
If treatment is stopped, appetite and weight can change again. Planning for maintenance therefore matters from the beginning rather than only when the prescription ends.
What this Wegovy guide does not cover
This page is deliberately an overview of how Wegovy injections work, broad suitability and the consultation and monitoring process. It does not provide a personalised dose schedule, quote a Wegovy price, promise stock or availability, or replace a prescribing assessment.
Dose options and product information can change, so use the latest prescription directions and patient leaflet for your exact product. Pricing is provider-specific and can change, while pharmacy service access depends on current availability and clinical eligibility.
Keeping those topics separate also helps you find the right information without confusing an educational medicine guide with a treatment-ordering or booking page.
Considering a weight-management consultation?
If you are exploring prescription weight-management support, you can read about the Kings Pharmacy weight-management service and the current route for making an enquiry. A consultation is an assessment, not a guarantee of a prescription or supply. The clinician will decide whether Wegovy or another approach is appropriate based on your health and the information you provide.
If you already use Wegovy and have a question about side effects, a missed dose, changing treatment or a new medical problem, contact Kings Pharmacy or speak to the clinician responsible for your care rather than changing the medicine yourself.
Frequently asked questions
Is Wegovy a GLP-1 medicine?
Yes. Wegovy contains semaglutide, which is a GLP-1 receptor agonist. It acts on GLP-1 receptors involved in appetite and food intake and also has effects on blood glucose. Wegovy is prescription-only and should be used only after an appropriate clinical assessment.
Who can use Wegovy injections?
Injectable Wegovy is licensed for weight management in adults with a BMI of at least 30 kg/m², or a BMI from 27 kg/m² to below 30 kg/m² with at least one weight-related health condition, alongside a reduced-calorie diet and increased physical activity. The product information also includes some adolescents aged 12 and over with obesity and body weight above 60 kg. Actual service eligibility can be narrower, and a prescriber must assess individual suitability.
Do I need a prescription for Wegovy?
Yes. Semaglutide for weight management is a prescription medicine in the UK. Whether you use an NHS or private route, it must be prescribed following an appropriate assessment. Do not buy weight-loss medicines from unregulated sources.
What happens in a Wegovy consultation?
The exact process varies, but the clinician normally needs to review information such as your BMI, medical history, current medicines, weight-related conditions, pregnancy or breastfeeding status where relevant, previous treatment and important safety risks. They should also explain side effects, warning symptoms, follow-up and what happens if treatment is not suitable.
How often is Wegovy monitoring needed?
There is no single follow-up interval that applies to every service or patient. Monitoring should be frequent enough to review tolerability, side effects, weight-management progress, dose decisions and any change in your health or medicines. Follow the schedule set by your prescriber or treatment service.
Medical information disclaimer
This article provides general information about Wegovy injections and does not provide personal medical advice, diagnosis or a prescription. Suitability, dosing, monitoring and treatment decisions depend on an individual clinical assessment and the current product information. If you develop severe symptoms or think you may be experiencing a medical emergency, seek urgent medical help.
